In vivo evaluation of [11C]-3-[2-[(3-methoxyphenylamino)carbonyl]ethenyl]-4,6- dichloroindole-2-carboxylic acid ([11C]3MPICA) as a PET radiotracer for the glycine site of the NMDA ion channel

Nuclear Medicine and Biology

Volumn 29, Issue 8, 2002, Pages 791-794

  Waterhouse, Rikki N ^a   Sultana, Abida ^a   Laruelle, M ^a  

^a New York State Psychiatric Institute ^*  (United States)

Author keywords

Glutamate; Glycine; NMDA; PET; Radioligand

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; GLYCINE; ION CHANNEL; N METHYL DEXTRO ASPARTIC ACID; RADIOLIGAND; TRACER; WARFARIN; 3 (2 ((3 METHOXYPHENYLAMINO)CARBONYL)ETHENYL) 4,6 DICHLOROINDOLE 2 CARBOXYLIC ACID; 3-(2-((3-METHOXYPHENYLAMINO)CARBONYL)ETHENYL)-4,6-DICHLOROINDOLE-2-CARBOXYLIC ACID; ANILIDE; DIAGNOSTIC AGENT; INDOLE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RADIOISOTOPE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CEREBELLUM; CONTROLLED STUDY; FRONTAL CORTEX; HIPPOCAMPUS; IN VIVO STUDY; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RAT; SYNTHESIS; THALAMUS; ANIMAL; ANTIBODY SPECIFICITY; BRAIN; CHEMISTRY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT; EVALUATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION;

ANILIDES; ANIMALS; BRAIN; GLYCINE; INDOLES; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; RADIOISOTOPES; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; WARFARIN;

EID: 0036848520     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(02)00335-9     Document Type: Article

References (30)

1. Carter C.J., et al. Ifenprodil and SL 82.0715 as cerebral antiischemic agents. III. Evidence for antagonistic effects at the polyamine modulatory site within the N-methyl-D-aspartate receptor complex. J. Pharm. & Exp. Therap. 253:(2):1990;475-482.
2. Dannhardt G., Kohl B.K. The glycine site on the NMDA receptor structure-activity relationships and possible therapeutic applications. Curr. Med. Chem. 5:(4):1998;253-263.
3. Lees K.R. Cerestat and other NMDA antagonists in ischemic stroke. Neurology. 49:(5 Suppl 4):1997;S66-S69.
4. Yoneda Y., Ogita K. Neurochemical aspects of the N-methyl-D-aspartate receptor complex. Neuros. Res. 10:(1):1991;1-33.
5. Reynolds I.J., Miller R.J. Multiple sites for the regulation of the N-methyl-D-aspartate receptor. Mol. Pharm. 33:(6):1988;581-584.
6. Becker J., Li Z., Noe C.R. Molecular and pharmacological characterization of recombinant rat/mice N-methyl-D-aspartate receptor subtypes in the yeast Saccharomyces cerevisiae. Eur. J. Biochem. 256:(2):1998;427-435.
7. Clements J.D., Westbrook G.L. Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor. Neuron. 7:(4):1991;605-613.
8. Harris R.A., et al. Actions of anesthetics on ligand-gated ion channels role of receptor subunit composition. FASEB J. 9:(14):1995;1454-1462.
9. Hirai H., et al. The glycine binding site of the N-methyl-D-aspartate receptor subunit NR1 identification of novel determinants of co-agonist potentiation in the extracellular M3-M4 loop region. Proceedings of the National Academy of Sciences of the United States of America. 93:(12):1996;6031-6036.
10. Laube B., et al. Molecular determinants of agonist discrimination by NMDA receptor subunits analysis of the glutamate binding site on the NR2B subunit. Neuron. 18:(3):1997;493-503.
11. Laurie D.J., Seeburg P.H. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur. J. Pharm. 268:(3):1994;335-345.
12. Lynch D.R., et al. N-methyl-D-aspartate receptors different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents. Mol. Pharm. 45:(3):1994;540-545.
13. Meoni P., et al. NMDA NR1 subunit mRNA and glutamate NMDA-sensitive binding are differentially affected in the striatum and pre-frontal cortex of Parkinson's disease patients. Neuropharm. 38:(5):1999;625-633.
14. Snell L.D., et al. Regional and subunit specific changes in NMDA receptor mRNA and immunoreactivity in mouse brain following chronic ethanol ingestion. Br. Res. Mol. Br. Res. 40:(1):1996;71-78.
15. Yamakura T., Shimoji K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog. Neurobiol. 59:(3):1999;279-298.
16. Giuffra M.E., Mouradian M.M., Chase T.N. Glutamatergic therapy of Huntington's chorea. Clin. Neuropharm. 15:(2):1992;148-151.
17. Heresco-Levy U., et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psych. 169:(5):1996;610-617.
18. Krystal J.H., et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harvard Review of Psychiatry. 7:(3):1999;125-143.
19. Leeson P.D., Iversen L.L. The glycine site on the NMDA receptor structure-activity relationships and therapeutic potential. J. Med. Chem. 37:(24):1994;4053-4067.
20. Stauch Slusher B., et al. Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice. J. Neural Trans. General Section. 97:(3):1994;175-185.
21. Takano K., et al. Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies. Stroke. 28:(6):1997;1255-1262. discussion 1263.
22. Haradahira T., Suzuki K. An improved synthesis of [11C]L-703,717 as a radioligand for the glycine site of the NMDA receptor. Nucl. Med. Biol. 26:(2):1999;245-247.
23. Haradahira T., et al. A prodrug of NMDA/glycine site antagonist, L-703,717, with improved BBB permeability 4-acetoxy derivative and its positron-emitter labeled analog. Chem. Pharm. Bull. (Tokyo). 49:(2):2001;147-150.
24. Dumont F., Slegers G. Synthesis and in vivo evaluation of 7-chloro-5-[I-123]iodo-4-oxo-1,4,-dihydroquinoline-2-carboxylic acid. Appl. Radiat. Isot. 48:(9):1997;1173-1177.
25. Haradahira T., et al. Improved brain uptake and cerebellar accumulation of an acid ester of NMDA/glycine site antagonist [11C]L-703,717. J. Labelled Cpd. Radiopharm. 42:(Suppl. 1):1999;S360-S362.
26. Rowley M., et al. Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J. Med. Chem. 40:1997;4053-4068.
27. Haradahira T., et al. A strategy for increasing the brain uptake of a radioligand in animals use of a drug that inhibits plasma protein binding. Nucl. Med. Biol. 27:(4):2000;357-360.
28. Di Fabio R., et al. Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia. J. Med. Chem. 42:(18):1999;3486-3493.
29. Fabio R.D., et al. Substituted indole-2-carboxylates as in vivo potent antagonists acting at the strychnine-insensitive glycine binding site. J. Med. Chem. 40:1997;841-850.
30. R.N. Waterhouse, et al., Synthesis and characterization of 4,6di-chloroindole-based radioligands for imaging the glycine site of theNMDA ion channel, J. Labelled Compds. Radiopharm. (submitted).